Pr Olivier ADOTEVI – Right Institute (Besançon, FR), Dr Marco ALESSANDRINI – Antion Biosciences (Geneva, CH), Pascale BOUILLÉ – Flash Therapeutics (Toulouse, FR), Dr Philippe BOUSSO – Institut Pasteur (Paris, FR), Emmanuel DEQUIER – « Grand défi Biomedicaments » (Paris, FR), Dr Marina DESCHAMPS – Right Institute (Besançon, FR), Pr Olivier DETANTE – Grenoble Institute of Neurosciences (Grenoble, FR), Dr Philippe DULIEU – RD Biotech (Besançon, FR), Dr Céline ELIE-CAILLE –FEMTO-ST Institute (Besançon, FR), Dr Christophe FERRAND – Right Institute (Besançon, FR), Dr Miguel FORTE – Bone Therapeutics (Charleroi, BE), Claire GERARD – Agence nationale de sécurité du médicament et des produits de santé, ANSM (Lyon, FR), Dr Mathilde GIRARD – ADHARA, subsidiary of the URGO Group (Chenôve, FR), Dr Mathieu GUERRIAUD – CREDIMI (Dijon, FR), Eric HALIOUA– PDC*line Pharma (Liège-Belgium), Dr Carole HENRY – Moderna Cambridge (Massachusetts, USA), Pr Roch HOUOT – UMR INSERM U1236 (Rennes, FR), Pr HUANG HE – Institute of Hematology, Zhejiang University (Hangzhou, PRC), Nathalie LABARRIERE – INCIT, UMR 1302 (Nantes, FR), Dr Suman MITRA – INSERM (Lille, FR), Sylvain PERRUCHE – RIGHT Institute (Besançon, FR), Pr Marco RUELLA – Center for Cellular Immunotherapies, U Penn (Philadelphia, USA), Phil CHALLIS – eTheRNA immunotherapies NV (Niel, Belgium), Dr Álvaro URBANO ISPIZUA – Clínic de Barcelona (Barcelona, SP), Julien VALTON – Cellectis (Paris, FR), Dr Andreas WALLNÖFER – Jeito Capital (Paris, FR)